Into pharma's roaring twenties
“I drained the last of my cocktail, gazing up at the ceiling. It was one of those moments that curls the hairs on your neck. At once, the grand scale of this labyrinth of cathedrals became clear, the desert wind blowing through the clever hieroglyphics carved into every available surface. I turned my head back down to ground level just in time to see the man draw back his fist in anger, and then.And then.With a piercing shriek, he lunged straight at my jaw –”Do you ever wake from a dream, marvelling at the inventiveness and detail of your subconscious mind? That disorienting moment where you lie blinking ...
Source: EyeForPharma - January 14, 2020 Category: Pharmaceuticals Authors: Paul Simms Source Type: news

Scaling patient engagement for deeper insights and better outcomes
 There are plenty of reasons to scale patient engagement. It drives a more patient-centric approach, can help create new services and enable better access and approval with payers and regulators.   But perhaps the simplest and most compelling reason for scaling engagement is its link to stronger outcomes, which has a cascade of business benefits.   “We should be doing this to get to better outcomes and that will also create a better commercial performance, because you will be in an environment where there is more money for innovation and you will be there with solutions that have a high outco...
Source: EyeForPharma - January 13, 2020 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

Pharma ’s new ally: the caregiver
While pharma and the wider healthcare sector are making patients more central to their innovation efforts these days, little consideration is given to caregivers. The role of the unpaid caregiver is one they would do well to consider more. Caregivers comprise an enormous, and largely untapped, reservoir of information and wisdom about the individuals they provide care for, says Schiffon Wong, Executive Director, Global Evidence& Value Development at EMD Serono.   “There is a significant opportunity when it comes to caregiver input into medical product evaluation. Understanding this can further our ...
Source: EyeForPharma - January 12, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Advancing RWE together with academia
  The promise of real-world Evidence (RWE) to offer a cost-effective way to help drive transformations in healthcare and drug development is dependent on significant improvements being made in the way real-world data (RWD) is collected and developed into robust evidence.  Challenges include limited access to databases, incomplete data and problems dealing with the enormous volume of data generated on a daily basis. Much time is spent on acquisition, cleansing, integration, standardisation and encryption, as well as analysis and extraction of insights.  This is where closer collaboration between pharma and...
Source: EyeForPharma - January 2, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Invest in MSLs to reap bigger gains
  If authenticity, data analysis and good customer rapport are the superpowers pharma needs most today, MSLs are the superheroes most able to wield them.  As the MSL ’s role continues to evolve from a supporting to a far more strategic one, pharma companies have much to gain from getting the most from this ever more important set of colleagues. Pharma therefore needs to invest in them and build MSLs ’ skills and knowledge in new areas, helping them adapt to new ways of interacting and use new technologies that can magnify their impact, says Emma Booth, Director, Medical Capabilities, EU Medical...
Source: EyeForPharma - December 31, 2019 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

eyeforpharma Awards: Recognizing and celebrating innovation
At the eyeforpharma Awards we strive to reward, support and incentivise innovation, especially when it comes to the value pharma offers patients and customers. We only recognize meaningful innovation which takes our industry, our reputation and our impact forward and the entries are measured objectively by external judges.  I was amazed by the quality of entries this year. With 500 nominations, our judges – a mixture of patients and health professionals – deliberated hard for many hours, finally settling on just 16 winners, each exemplifying the very best work in pharma.   By ‘best’...
Source: EyeForPharma - December 19, 2019 Category: Pharmaceuticals Authors: Paul Simms Source Type: news

Telemedicine: The future of clinical trials?
Telemedicine – or remote visits – has traditionally been used for patient-physician consultations and the delivery of health care. Today, the value of telemedicine in clinical trials is creating a buzz. With the promise of greater access to research and reduced attrition, what else is driving pharma’s move towards decentralized trials?  For Boehringer Ingelheim, patient-centricity is at the heart of its drive to conducting decentralized clinical research, says Brandon Maggio, Associate Director. “A patient’s geographic location and/or socioeconomic status is one of the largest barriers t...
Source: EyeForPharma - December 13, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Patients united: Bringing the patient voice to genetics research
Patients have always been at the heart of the Cure Parkinson ’s Trust (CPT), co-founded by four individuals with PD in 2005. Today it has 16,000 forum members with Parkinson’s disease (PD), about 2,000 PD patients in clinical trials, and approximately 1,500 PD patients attending the World Parkinson’s Congress.   Together with several external research and fundraising institutes, the charity brings together all the personal experience and scientific expertise needed to propel its patient-centric mission to find a cure. “Having a broad range of personal and professional expertise available ...
Source: EyeForPharma - December 5, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Five eye-openers from the MIT Healthcare Panel
This past October, I sat down with four transformational healthcare leaders at the MIT Museum in Cambridge, MA.  The panel represented a mix of the three archetypes of Prophet’s Evolved Healthcare Enterprise:  Transformers – mature, traditional healthcare companies seeking to better leverage modern approaches to growth, Invaders – well-established, fast growing non-healthcare organizations moving into the healthcare ecosystem.  And Creators – next-generation healthcare companies built from the ground up. •Kelsey Yevak, Transformer: Sanofo is a “Transformer,” a lo...
Source: EyeForPharma - November 28, 2019 Category: Pharmaceuticals Authors: Paul Schrimpf Source Type: news

The online health trends pharma should be tapping into
Each year digital folk all over the world look to the Internet Trends report, delivered by Bond Capital founder Mary Meeker, for a summary of the most important emerging online technologies and consumer behaviours.    The 2019 report underlines the strength of some trends familiar to pharma and points to some unsettling implications for the industry if it cannot respond appropriately. Along with some general online trends - the growing consumption of images and video, the rise of the podcast and the ongoing spread of Amazon Echo - the report highlights some important consumer healthcare trends.  Perhaps th...
Source: EyeForPharma - November 20, 2019 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Taking the plunge into digital
There are so many opportunities for medical affairs to harness the potential of digital tools it ’s hard to know where to start.  Virtual meetings, cloud-based data sharing and mass intelligence gathering on patients and HCPs are some of the most obvious opportunities. Multiple online, social and other media meanwhile can transform the ability of medical affairs to help healthcare providers and patients find the information they need, when they need it, in the form they need it.  But these are early days, and it ’s hardly controversial to say that medical affairs is still generally only taking baby ...
Source: EyeForPharma - November 13, 2019 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Putting a Price on Life: Is the Answer Outside Pharma?
 To cure the previously incurable we must take two giant steps: the first towards better understanding the science behind a cure, and the second towards ensuring accessibility for those people in need of the treatment.   Although there is still much to discover, we got the science right some time ago. The first gene replacement therapy – Gendicine (Shenzhen SiBiono GeneTech) – was approved in China in 2003 and has been successfully administered to more than 30,000 patients with head and neck squamous cell carcinoma. A single dose of this medication costs $400.  Another example of early ...
Source: EyeForPharma - November 4, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

Breaking out of data silos in commercial
 The healthcare business generates over a trillion gigabytes every year. That number is also known as one zettabyte –you may well want to get used to the higher order counts when it comes to data.  This zettabyte count will double, Moore ’s Law style, every two years. This explosion of data should portend the best of times: Just think about the applications and algorithms that could run on all those datapoints and the insights and innovation they could deliver.  The reality right now is somewhat more prosaic though. Most pharma companies are today drowning in data lakes, yet they contin...
Source: EyeForPharma - October 22, 2019 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

Breaking out of data silos in commercial
 The healthcare business generates over a trillion gigabytes every year. That number is also known as one zettabyte –you may well want to get used to the higher order counts when it comes to data.  This zettabyte count will double, Moore ’s Law style, every two years. This explosion of data should portend the best of times: Just think about the applications and algorithms that could run on all those datapoints and the insights and innovation they could deliver.  The reality right now is somewhat more prosaic though. Most pharma companies are today drowning in data lakes, yet they contin...
Source: EyeForPharma - October 21, 2019 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

Free webinar: Deeper patient insights for stronger patient outcomes
Channels: Patients and MedicalImage: URL: https://www.eyeforpharma.com/barcelona/webinar/?partner=efp-website&utm_source=efp%20website&utm_medium=banner&utm_campaign=IQVIA%20webinarExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - October 18, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Empowering patients with the right data at the right time
We ’ve all read about the potential for data to transform healthcare by enabling patients to better understand their conditions and engage better in their treatment.  Now a handful of pioneers are starting to demonstrate the potential and to justify some of the hype. Some rapid improvements in outcomes and adherence point the way to a future in which agile pharma teams routinely work with ever more real-time, real-world data to rapidly and iteratively improve patient insights and outcomes. In the era in which payments will increasingly be tied to results, such innovations should be of huge value, and w...
Source: EyeForPharma - October 17, 2019 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Five Shifts Toward Consumer-Centric Transformation
In the 1990s American physician Tom Ferguson coined the concept of the “e-patient”. Ferguson, an advocate for increasing the role of the patient in managing their own healthcare, defined e-patients as empowered: engaged, equipped and enabled. The e-patient was a concept limited to direct interactions with healthcare organizations and at Prophet we have expanded the concept of the e-patient and evolved it into the ‘e-consumer’. If healthcare organizations are to serve the e-consumer and engage, empower, equip, and enable them, they will need to make a shift and put the consumer at the cente...
Source: EyeForPharma - October 14, 2019 Category: Pharmaceuticals Authors: Anonymous Source Type: news

Putting patients front and center
‘Access'and ‘patient value’ are familiar terms in the pharma industry, but so often they are used in the abstract with little sense of what they mean to people at the receiving end of healthcare.  Liz Lewis, Head of Global Oncology Patient Value, Policy, and Access at Takeda Oncology, knows better than most, and knows what these words truly mean to people living with cancer around the globe.  Her experience started in childhood. While in high school, she spent time working in the office of her physician father, gaining an understanding of how the reimbursement process worked. Her father would ...
Source: EyeForPharma - September 20, 2019 Category: Pharmaceuticals Authors: astone Source Type: news

Towards Patient Preferred Trials
The need to reform the clinical trials process with the patient in mind is becoming ever more apparent. Given the expense and time it takes to find and retain suitable trial candidates, making a trial scientifically rigorous is no longer enough. It must also be compatible with a patient ’s lifestyle.   Participants in clinical trials are not numbers on a spreadsheet. They are customers, consumers, patients and people with complexities, preferences and nuances. Increasingly they are demanding more choice and more involvement in their treatment journey.  New technology that enables pharma to digitise t...
Source: EyeForPharma - September 18, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Design: Pharma ’s next frontier
Banking hadn ’t changed in decades before disruptive, challenger banks like Monzo gained cult status among customers for their ease of use. These challengers fulfilled needs people didn’t even know they had, but soon came to rely on – individually relatively small benefits such as choosing PINs, blocking l ost cards from an app or receiving geo-tagged purchase notifications – but collectively amounting to a very different experience.  What brings them together is the quality of thinking behind the consumer experience. Today, parts of pharma are adopting different user-centred design approaches...
Source: EyeForPharma - September 16, 2019 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

The Jan Twomey story — Empowering and connecting
Earlier this year Jan had a big decision to make. In her early 60s, she could leave pharma and pursue her dream to join the crew on the Mercy ship – serving patients in need around Africa - or stay with Takeda through their transition and lead the Medical team for Oceania. She chose to stay and here’s why.  “It gives me a lot of pleasure helping my team to be happy and thrive,” says Jan.  Jan was raised to really think about society and people. Her father encouraged vigorous debate, pushing Jan to defend her beliefs and statements. As a child of the 70’s, Jan was on a mission to...
Source: EyeForPharma - September 6, 2019 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

MSL webinar
Channels: MedicalImage: URL: https://www.eyeforpharma.com/barcelona/webinar2/?partner=efp-website-listing&utm_source=efp%20website&utm_medium=efp%20websiteExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - September 4, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

No patents. No launches. No stages. Welcome to modern pharma.
  It ’s not enough to have a customer experience strategy, give it a little funding, and hope it somehow takes off.  Companies outside of healthcare that are winning in experience treat it like a core product.    That means they have a senior leader overseeing a team and full P&L dedicated to the success of that experience, both the overall and micro-moments.  What is keeping pharma companies from doing this?  If you follow the money, things become clear.  Traditional confines based on milestone dates put a tremendous amount of stress on an organization to maximize its investm...
Source: EyeForPharma - September 3, 2019 Category: Pharmaceuticals Authors: Anonymous Source Type: news

Whose Data is it Anyway?
When cancer patient Pete started to look into who held records about his illness and treatment, mapping the journey of his data proved to be no easy feat. Tracking where his information was held, had been used, and might yet be used in the future took tens of hours of searching and filing requests.     As a member of use MY data, a UK-based patient group working to build confidence in the use of healthcare data, he is helping to demonstrate how much work the industry has to do when it comes to transparency around patient data.     This lack of accessibility, coupled with the wider suspicion ...
Source: EyeForPharma - August 30, 2019 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Creating a Patient Trial Community
When TJ Sharpe was diagnosed with Stage 4 melanoma in August 2012, his future looked bleak. He was 37 years old with two young children, the median lifespan for patients with his diagnosis was 18 months and treatment options were limited.Thanks to some knowledge of the pharmaceutical industry he soon realised his best chance of survival was to find a clinical trial. It was a daunting prospect, but his resolve was solid and, after undergoing six surgical operations and four immunotherapy treatments across two different clinical trials, he lived to tell the tale.“I was lucky,” says Sharpe, “I was aware of c...
Source: EyeForPharma - August 13, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Unleashing AI ’s potential in clinical trial recruitment
The onerous cost of clinical trials in time, money and effort is well documented. The average clinical trial process lasts between 7.5 and 12 years, studies estimate, with costs ranging from $161M - $2.6B per drug. Just 14% of clinical trials are successful and only one in ten drugs entering Phase 1 ends up being approved by the FDA.   Recruitment is a significant source of the problem. According to Christina Busmalis, director of global life sciences at IBM Watson Health,80% of clinical trials do not finish on time and the reason for this, in 86% of cases, is that they do not meet target recruitment on time. &ld...
Source: EyeForPharma - July 29, 2019 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

Making it about the patient, with the patient
While attending a recent eyeforpharma conference, the words of one particular speaker stuck with Laurie Meyers.“There was a patient who spoke and said something that struck me to the core. He said, ‘if you do it without us, then it’s not about us’. Those words said it all for me, for Genentech, and for all of our industry partners,” says Meyers. “We must involve patients early and often in co-cre ating and ideating on solutions meant for them.”Genentech was already working to engage with patients in a more meaningful way before she heard this speaker but his observation has since b...
Source: EyeForPharma - July 26, 2019 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news

The Tausif ‘Tosh’ Butt Story –Different lenses, different lessons
“Sometimes you need to see things from a different lens,” says Tosh Butt (SVP in Latin Am and Brazil for AstraZeneca).  That different lens has been in Tosh’s back pocket throughout his life and is helping him better serve his team and the doctors and patients they serve. Read on to hear how the different lenses from three experiences (a handbag factory, Paula and a newspaper clipping) changed Tosh’s story. Thank you Tosh. We are so grateful you brought your wisdom and passion to our industry. You are truly a purpose-driven, inspirational leader! 3 lenses that shaped Tosh ’s lif...
Source: EyeForPharma - July 24, 2019 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Cue Biopharma: Diagnostic & disease detection to transform biopharma
Pr écis: How Cue BioPharma is taking the next leap in drug discovery and focusing on diagnostic and detection. Anish Suri, Chief Scientific Officer, speaking on the keynote stage at eyeforpharma PhiladelphiaYouTube URL: https://www.youtube.com/watch?v=X4kBSMt_7KUVideo Thumbnail Image: Channels: MedicalMultichannelPatients and MedicalClinicalTags: preventative medicine (Source: EyeForPharma)
Source: EyeForPharma - July 24, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Dr Avi Spira: Janssen's use of new technology to intercept lung cancer
Pr écis: Dr Avi Spira, Global Head of Johnson& Johnson's Lung Cancer Initiative on their use of ML, Robotics and Molecular Technology to intercept lung cancer.YouTube URL: https://www.youtube.com/watch?v=oe5T5RF1Z3EVideo Thumbnail Image: Channels: Access and EvidenceMedicalTags: Janssen (Source: EyeForPharma)
Source: EyeForPharma - July 24, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

The Eisenbahnscheinbewegung Risk
Pr écis: Kris Sterkens, Company Group Chairman, Europe, Middle East and Africa at Janssen speaking on the closing keynote stage at eyeforpahrma Barcelona 2019.YouTube URL: https://www.youtube.com/watch?v=rKp04QLrkQgVideo Thumbnail Image: Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalTags: Janssen (Source: EyeForPharma)
Source: EyeForPharma - July 24, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Up Close and Personal: The Naji Gehchan Story – On a mission to improve life
From the moment I met Naji Gehchan, I loved his positive energy. Later when I learned of his path that developed that energy, I appreciated it even more. Naji has never shared this story, until now. Read how a childhood avoiding bombs, the Red Cross and a chance internship created the man he is today. He is living a mission to improve as many lives as possible – both inside and outside his organization.   A few years ago, Naji was sitting in a workshop at Disney University in Orlando. As an icebreaker, the facilitator asked each participant for their first childhood memories. One after another, people talk...
Source: EyeForPharma - July 8, 2019 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Up Close and Personal – The Bill Strickland Story
Bill Strickland's (Head of Global Medical Resources at AstraZeneca) aptitude for science came naturally. His father taught Chemical Engineering at the University of Arkansas and his mother was an Ultrasonographer He loved complex problems and had an eye to see opportunities and make improvements. His mom always said he was the “but why” kid. How do you get someone to the moon? How do you cure cancer? Bill wanted to know.   Between the ‘puzzling’ and games they played as a family to test their minds and the incredible stories his mom brought home from the hospital; Bill was hooked on solvi...
Source: EyeForPharma - June 27, 2019 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Putting The I in Pills
You can bet your bottom dollar that as your eyes scroll over these words there is a room full of pharma executives somewhere thrashing out a strategy towards precision medicine. A topic that was once confined to blue-sky conversations is fast becoming a reality.  (Source: EyeForPharma)
Source: EyeForPharma - June 27, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Cross Team Collaboration: The Not So Secret Sauce of Success
Eli Lilly is now several years into just such a transformation, moving from the old advertising and sales model towards integrated and personalized customer engagement.  The aim of the transformation is to serve consumers and health care providers with the right blend of content in the manner of their choosing...Pleaselogin to view the whole article - orsubscribe hereFor a free two week trial to EyeforPharma online, pleaseclick here.Related Content: Cancer Initiative Nets Collaboration AwardMultiple channels or multichannel: In search of digital communications that inspire partnershipsMaking The Digital LeapPrim...
Source: EyeForPharma - June 27, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

In The end, Rare Drug Pricing Will Hurt Pharma Just As Much As Patients
There ’s been an odd-sounding word circulating in the English headlines recently.The word is Orkambi; a drug created by Vertex that treats approximately 40% of people born with the genetic condition, cystic fibrosis. It is the second drug to market in a promising pipeline that targets the CFTR mutation.   True gene therapy it isn’t, but it represents a near-first for a biotech firm, by successfully altering the shape and function of a protein[1]. And priced at £105,000 per patient per year, it is the latest in a long line of medicines the NHS can’t afford.Orkambi has been licensed by the EMAsin...
Source: EyeForPharma - May 24, 2019 Category: Pharmaceuticals Authors: Elly Aylwin-Foster Source Type: news

eyeforpharma awards_nominations open
Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercialImage: URL: https://eloqua.eyeforpharma.com/LP=23914?utm_source=webpage%20tracked%20link%205086&utm_medium=eyeforpharma%20homepageExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - May 15, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Francesco Lucarelli
Company Notes: Francesco Lucarelli joined HCB Health in 2016 and currently serves as managing director of the agency ’s Bio Pharma division. He is responsible for all elements of the division’s work creation, delivery and production; internal team management; and external client development and satisfaction. During his more than 20 years in the pharmaceutical and medical device industries, Francesco has overse en product launches and developed results-driven strategy in a wide variety of leadership roles. He has broad experience in strategic planning and commercialization strategy, client services and busi...
Source: EyeForPharma - April 9, 2019 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Challenging Goliath – How Underdogs Stand A Fighting Chance
We all love an underdog story. Who isn ’t moved by the passion, grit, and determination that drives an outsider to overcome near-impossible odds? Rudy, Rocky, Million Dollar Baby, Miracle – Hollywood has captured our hearts while cashing in on this timeless trope. When it comes to the biopharmaceutical arena, however, we sometimes lo ok down upon the upstart rather than embrace its potential.Smaller companies and products often face the Herculean challenge of going up against the super-power, mega-sized pharma companies. Smaller budgets, operational teams, and fewer sales reps are viewed as insurmountable odds....
Source: EyeForPharma - March 24, 2019 Category: Pharmaceuticals Authors: Francesco Lucarelli Source Type: news

Catherine Calarco
Company Image:  (Source: EyeForPharma)
Source: EyeForPharma - March 6, 2019 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news